AVEO Pharmaceuticals, Pipeline Review and Potential Catalysts
NEW YORK, NY / ACCESSWIRE / April 10, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on AVEO Pharmaceuticals, Inc. (AVEO) is a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
In late January, AVEO shares dropped significantly from $1.80 to $.70 per share. In recent weeks the company shares have experienced a rebound to the current level of $1.08 per share.
See what's going on at AVEO that may be catalysts for its stock READ MORE
Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/aveo-pharmaceuticals/
In December 2015, AVEO entered into a license agreement with EUSA Pharma, following which the former granted exclusive right to develop, manufacture and commercialize Fotivda in Europe to EUSA. AVEO receives milestone payments and royalties on Fotivda sales in Europe.
Last November, AVEO announced that it will earn a $2-million milestone fee from EUSA Pharma, triggered by the commercial launch and reimbursement of Fotivda in Germany.
Get the analysts review and company financial guidance through 2019 READ MORE
Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/aveo-pharmaceuticals/
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT: editor@tradersnewssource.com
SOURCE: Traders News Source
View source version on accesswire.com:
https://www.accesswire.com/541431/AVEO-Pharmaceuticals-Pipeline-Review-and-Potential-Catalysts
